Poor Cardiovascular-Kidney-Metabolic Health Increases Psoriasis Risk
WEDNESDAY, Sept. 10, 2025 -- Poor cardiovascular-kidney-metabolic (CKM) health is associated with an increased risk for psoriasis, especially for those with high genetic risk, according to a study published online July 18 in the Journal of the European Academy of Dermatology and Venereology.
Gang Zheng, from China Medical University in Shenyang, and colleagues examined the associations among CKM status, genetic risk, and the risk for developing psoriasis in a prospective cohort study involving 392,454 participants free of psoriasis from the U.K. Biobank. The presence of metabolic risk factors, chronic kidney disease, and cardiovascular disease defined CKM syndrome, which was categorized into five stages.
The researchers found that the multivariable-adjusted hazard ratios for developing psoriasis were 1.21, 1.38, 1.64, and 1.72 for individuals with CKM stages 1, 2, 3, and 4, respectively, compared with stage 0. Compared with those at stage 0 with low genetic risk, participants with CKM stage 4 and high genetic risk had the highest risk for psoriasis (hazard ratio, 2.82). In terms of development of psoriasis, a significant positive additive interaction was seen between advanced CKM stages and high genetic risk (relative excess risk due to interaction, 0.82). Advanced CKM stage (stage 4) was associated with a greater reduction in life expectancy (2.03 years) within the psoriasis population.
"Our findings highlight the critical importance of early detection and timely intervention during the initial CKM stages to mitigate the risk of psoriasis and enhance life expectancy," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Read this next
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...
Patients With Extreme Obesity Face Limitations to Accessing Specialty Care
TUESDAY, Sept. 30, 2025 -- Patients weighing more than 450 lb face considerable limitations when attempting to access specialty care, according to a research letter published...
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
TUESDAY, Sept. 30, 2025 -- Patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have better long-term outcomes compared with those taking...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.